All 3 α 2 -AR subtypes are present in the neonatal rat cochlea and on inner HCs (IHCs) and outer HCs (OHCs) on postnatal (P) days P3 and P8 [Cai et al., 2013b] . In addition, the rat organ of Corti (OC) shows adrenergic innervation [Drescher et al., 2006] . Interestingly, experiments suggest that sympathetic fibers with noradrenaline as the postganglionic neurotransmitter affect the susceptibility to noise-induced hearing loss [Bielefeld and Henderson, 2007] .
Although the mechanisms underlying the neuroprotective effects of brimonidine are not entirely understood, PI3 kinase-dependent pathways appear to be involved [Knels et al., 2008; Yukita et al., 2016] . Specifically, the PI3 kinase signaling pathway is involved in the HC survival of gentamicin-induced toxicity [Chung et al., 2006] , and our group recently showed that protein kinase B (Akt) is involved in HC survival . Notably, exposure to brimonidine can lead to Akt phosphorylation [Kim et al., 2007; Lai et al., 2002; Tatton et al., 2001] , and brimonidine exerts its neuroprotective effects by activating the MAPK pathway [Fujita et al., 2013; Harun-OrRashid et al., 2014; Lai et al., 2002] . After exposure to brimonidine, there is phosphorylation of the extracellular signal-activated kinases 1/2 (Erk1/2) in injured retinal homogenates [Fujita et al., 2013] or as a physiological response to α 2 -AR activation in uninjured retinal homogenates [Lai et al., 2002] and chicken Müller cells [HarunOr-Rashid et al., 2014] . Phosphorylation of Erk1/2 has especially been shown to mediate HC survival [Bas et al., 2012; Kurioka et al., 2015] , and one way to protect OHCs from gentamicin-induced toxicity is increased activation of MAPK/Erk [Battaglia et al., 2003] .
In addition to these molecular mechanisms, brimonidine has also been shown to have neuroprotective properties via N-methyl-D -aspartate (NMDA) inhibition [Dong et al., 2008; Han and Wu, 2002] , growth factor upregulation [Gao et al., 2002; Kim et al., 2007; Lonngren et al., 2006] , and involvement in apoptotic pathways [Cai et al., 2013a; Lai et al., 2002] . Furthermore, brimonidine inhibits protein kinase A [Grueb et al., 2008] . Interestingly, Navaratnam et al. [1996] demonstrated that the proliferation and regeneration of the avian auditory epithelium depends on the activation of protein kinase A, which is cAMP-dependent, and that inhibition of protein kinase A correlates with decreased regeneration.
Little is known about the role of the α 2 -AR in HCs. The neuroprotective effects of brimonidine on different cell types and the presence of all 3 α 2 -AR subtypes in HCs prompted us to examine whether brimonidine could protect mammalian HCs from gentamicin-induced toxicity.
If we found a protective effect, we also wished to investigate whether it could be blocked by the α 2 -AR antagonist yohimbine. We further examined whether brimonidine changed the expression levels of the α 2 -AR protein. Finally, we investigated whether this drug could change Erk1/2 and Akt phosphorylation levels in OCs.
Materials and Methods

Drugs and Antibodies
Brimonidine tartrate (Y0001658), yohimbine hydrochloride (Y3125), gentamicin, and penicillin (SP600125) were obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Primary antibodies against the following proteins were used at the indicated dilutions: phospho-p44/42 MAPK (p-Erk1/2)-Thr202/ Tyr204 (4370) and phospho-Akt-Ser473 (4060) at 1: 1,000, and p44/42 MAPK (Erk1/2; 4695) and Akt (9272) at 1: 500 (all from Cell Signaling, Bioconcept, Allschwil, Switzerland); GAPDH at 1: 5,000 (ab8245; Abcam, Labforce AG, Nunningen, Switzerland), and α 2a -AR at 1: 500 (PA1-048; Affinity Bioreagents, Golden, CO, USA).
OC Dissection
All animal procedures were carried out in Basel, Switzerland, according to an animal research protocol that was approved by the Animal Care Committee of the Canton of Basel, Switzerland. All experiments were carried out with OCs from 5-day-old Wistar rat pups (Janvier Labs, Le Genest-Saint-Isle, France). The OCs were dissected from the skull and then transferred to cell culture plates with Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 25 m M of HEPES, and 30 U/mL of penicillin, and incubated at 37 ° C in 5% CO 2 .
Tissue Culture HC damage was induced by exposure to 400 μ M gentamicin for 48 h for HC damage experiments, or for 8 or 24 h for the Western blot analyses. Before exposure to gentamicin, the OCs were pretreated with brimonidine (1, 10, or 100 μ M ) and yohimbine (10 μ M ) for 20-24 h. Yohimbine is an α 2 -AR antagonist that has been used to block the effects of brimonidine that are mediated by the α 2 -AR [Cai et al., 2013a; Harun-Or-Rashid et al., 2014 Lai et al., 2002] . The concentrations we used were based on a study that found that 10 μ M of yohimbine blocked the effects of several concentrations of brimonidine (0.01-1 μ M ) [Cai et al., 2013a] .
HC Count
After treatment, the OCs were fixed, permeabilized, and stained with Alexa Fluor 568 phalloidin (Invitrogen AG, Basel, Switzerland). The images were acquired using the Nikon A1R laser confocal microscope (Nikon AG Instruments, Egg, Switzerland). The surviving HCs were counted in a section corresponding to 20 IHCs at different sites of the basal and middle turn of each OC in randomly selected fields. The apical turn was not used in our experiments since we observed almost no damage in the apex of the cochlea at our chosen gentamicin concentration. Previous experiments showed that the base of the cochlea is more susceptible to gentamicin damage than the apex [Sha et al., 2001] . The IHCs and
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OHCs were counted to determine HC survival. If there was a gap in the normal ordered array of HCs, cells were considered to be missing because they had undergone apoptosis.
Immunoblotting
To prepare tissue lysate, the basal and middle turns of 6-7 OCs per experimental condition were dissected and cultured as described above. After treatment, the explant tissue was lysed with 20 μL per OC of T-Per Tissue Protein Extraction Reagent (Thermo Fisher Scientific, LuBio Science, Lucerne, Switzerland) containing phosphatase/protease inhibitors (Roche, Indianapolis, IN, USA). Proteins were separated by electrophoresis and blotted onto a polyvinylidene difluoride membrane. The membrane blocking and antibody incubation steps were performed using the iBind Flex Western System (Thermo Fisher Scientific) according to the manufacturer's protocol. The bands were visualized via chemiluminescence using West Femto SuperSignal (Thermo Fisher Scientific). The blotted membranes were first used to visualize the phosphorylated forms of the proteins, then stripped with Restore PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific) and reused to analyze the corresponding amounts of total protein. For each membrane, GAPDH was used as a loading control. ImageJ software (NIH) was utilized to calculate the relative densities of the specific protein bands for each condition. The amount of phospho-Erk1/2 and phospho-Akt relative to the total Erk and Akt protein was calculated. The ratio of the relative amount of α 2A -AR to GAPDH was also calculated. For the Western blot analysis, 3 biological replicates were used for the 24-h incubation, and 2 biological replicates were used for the 8-h incubation. An incubation time of 24 h was chosen because Erk1/2 activation was observed in previous studies after 24 h [Cai et al., 2013a; Harun-Or-Rashid et al., 2015] . Chung et al. [2006] observed Akt activation after exposure to gentamicin for 6 h. We decided to investigate Akt activation after exposure to gentamicin for 8 h.
Statistical Analysis
All data are presented as the mean ± standard deviation. The statistical analysis was performed using Prism 6 (GraphPad software, La Jolla, CA, USA). We used 2-way ANOVA and the Tukey multiple comparisons test to analyze HC damage. For the protein ratios, we used the Kruskal-Wallis 1-way ANOVA test and Dunn multiple comparisons test. The results were considered statistically significant at p < 0.05. 
Results
Brimonidine and Yohimbine Are Not Toxic to HCs in vitro
To exclude possible toxic effects of brimonidine and yohimbine on HCs, OCs were incubated with the concentrations of brimonidine (1, 10, 100 μ M ) and yohimbine (10 μ M ) used in later experiments. There was no significant difference in cell number between the control group and OCs exposed to different concentrations of brimonidine ( Fig. 1 a) . OC explants exposed to brimonidine alone showed 3 complete rows of OHCs and a complete row of IHCs, as in OCs treated with culture media alone ( Fig. 1 b) . There was also no significant difference in the number of surviving HCs between the control group and OCs exposed to yohimbine ( Fig. 1 c) . OC explants exposed to yohimbine alone showed 3 orderly rows of OHCs and a single row of IHCs, as in the control group ( Fig. 1 d) . Thus, brimonidine and yohimbine were not toxic to HCs.
Brimonidine Protects OHCs from GentamicinInduced HC Damage in vitro
As expected, there was a significant loss of OHCs and IHCs after exposure to gentamicin ( Fig. 2 a) . After 48 h of exposure to 400 μ M gentamicin, there were fewer surviving OHCs (42.5 ± 12.3) and IHCs (14.6 ± 5.4) compared to untreated OHCs (59.4 ± 2.1) and IHCs (19.0 ± 2.2) in a section of 80 HCs ( Fig. 2 a, b) . The survival of OHCs in OCs exposed to gentamicin and 100 μ M brimonidine (51.8 ± 12.6) was significantly higher than in OCs exposed to gentamicin alone (42.5 ± 12.3, p < 0.0001; Fig. 2 a, b) . 
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Yohimbine Inhibits the Protective Effect of Brimonidine on Gentamicin-Induced OHC Damage in vitro
After exposure to gentamicin for 48 h, the number of surviving OHCs (36.5 ± 9.1) and IHCs (11.2 ± 3.4) in a section of 80 HCs was significantly lower than the number of surviving OHCs (59.0 ± 2.1, p < 0.0001) and IHCs (18.1 ± 2.7, p < 0.0001) in untreated OCs ( Fig. 3 a) . In OCs exposed to gentamicin and brimonidine, the number of surviving OHCs (49.6 ± 10.1) was significantly higher than the number of surviving OHCs that were exposed to gentamicin alone (36.5 ± 9.1, p < 0.0001; Fig. 3 a) . There were significantly fewer surviving OHCs in OCs exposed to gentamicin, brimonidine, and yohimbine (33.9 ± 7.8) versus those exposed to gentamicin and brimonidine (49.6 ± 10.1, p < 0.0001; Fig. 3 a) . Most of the OHCs survived in OCs that were exposed to gentamicin and brimonidine; the OCs showed few gaps in the normal ordered array of HCs ( Fig. 3 b) . Notably, in OCs exposed to yohimbine, brimonidine, and gentamicin, multiple OHCs underwent apoptosis, creating a gap in the normal ordered array of HCs ( Fig. 3 b) . Hence, the protective effect of brimonidine on OHCs was inhibited by yohimbine. The Expression Levels of the α 2a -AR Protein Are Not Changed by Exposure for 8 h to Brimonidine, Yohimbine, and/or Gentamicin The effects of brimonidine are mediated by the α 2 -AR. Interestingly, brimonidine is a strong agonist of the α 2a -AR subtype but only a weak agonist of the α 2b and the α 2c -AR subtypes [Peltonen et al., 1998 ]. We investigated the expression levels of the α 2a -AR protein to examine whether brimonidine upregulated α 2a -AR expression. Exposure of OCs to 400 μ M of gentamicin, 100 μ M of brimonidine, and/or 10 μ M of yohimbine for 8 h did not affect the expression level of the α 2a -AR protein ( Fig. 4 a, b) .
Brimonidine Does Not Significantly Change the Activation Levels of the Erk1/2 and Akt Proteins after 8 or 24 h of Exposure
Phosphorylation of Erk1/2 mediates HC survival [Bas et al., 2012; Kurioka et al., 2015] , and brimonidine promotes Erk1/2 phosphorylation [Fujita et al., 2013; Lai et al., 2002] . We did not find any significant changes in the phosphorylation levels of Erk1/2 after exposure to gentamicin. After 8 h, the activation level of the Erk1/2 protein was lower in OCs exposed to gentamicin compared to the control group ( p > 0.99; Fig. 5 a, b) . Brimonidine showed a tendency to increase the activation level of the Erk1/2 protein ( Fig. 5 a, b) . After exposure to brimonidine for 24 h, the Erk1/2 protein activation level showed the same tendency as after treatment for 8 h ( Fig. 5 c, d) .
Our group recently showed that Akt is involved in HC survival , and brimonidine leads to the phosphorylation of Akt [Kim et al., 2007; Lai et al., 2002; Tatton et al., 2001] . However, in this study, the increases in the phosphorylation levels of Akt after exposure to brimonidine were not statistically significant. The activation level of the Akt protein was reduced after 8 h in OCs exposed to gentamicin alone compared to the control group The effects of brimonidine, yohimbine, and gentamicin on the levels of activated Erk and Akt proteins. a Representative Western blots of p-Erk and total Erk. b Quantification of the p-Erk/Erk ratio after exposure to the indicated concentrations of gentamicin, brimonidine, and/or yohimbine for 8 h. Exposure to brimonidine did not significantly change the levels of activated Erk1/2. Two independent experiments were performed with n = 6-7 pooled explants for each condition. c Representative Western blots of p-Erk and total Erk. d Quantification of the p-Erk/Erk ratio after exposure to the indicated concentrations of gentamicin, brimonidine, and/or yohimbine for 24 h. Three independent experiments were performed with n = 6-7 pooled explants for each condition. e Representative Western blots of p-Akt and total Akt. f Quantification of the p-Akt/Akt ratio after exposure to the indicated concentrations of gentamicin, brimonidine, and/or yohimbine for 8 h. Brimonidine did not significantly change the levels of activated Akt protein. Two independent experiments were performed with n = 6-7 pooled explants for each condition. g Representative Western blots of p-Akt and total Akt. h Quantification of the p-Akt/Akt ratio after exposure to the indicated concentrations of gentamicin, brimonidine, and/or yohimbine for 24 h. Three independent experiments were performed with n = 6-7 pooled explants for each condition. There was no significant difference in the α 2a -AR/GAPDH ratio in explants exposed to the indicated concentrations of gentamicin, brimonidine, and/or yohimbine versus untreated explants (control). Two independent experiments were performed with n = 6-7 pooled explants for each condition. The explants were exposed to gentamicin, brimonidine, and/or yohimbine for 8 h. GAPDH was used as a loading control. Values are shown as means + SDs. ( p = 0.08); however, this result did not reach statistical significance ( Fig. 5 e, f) . Brimonidine showed a tendency to increase the Akt protein activation level ( Fig. 5 e, f) . After 24 h of exposure to brimonidine, we observed no further increase in Akt protein activation ( Fig. 5 g, h) .
Discussion
Previous studies have shown that IHCs and OHCs in the rat neonatal cochlea express all 3 α 2 -AR subtypes [Cai et al., 2013b] . The α 2 -AR mediates the physiological response to the catecholamines adrenaline and noradrenaline, and adrenergic innervation of the OC has been shown [Drescher et al., 2006] . However, the role of the α 2 -AR in HCs is currently unknown. Because we observed that brimonidine has protective effects in the visual system and in the spiral ganglion, we wanted to investigate whether brimonidine had protective effects on auditory HCs in vitro.
Brimonidine Protects OHCs from GentamicinInduced Toxicity
Exposure to gentamicin leads to a significant loss of IHCs and OHCs. The gentamicin-induced damage to HCs that we observed was similar to that observed in our earlier study [Glutz et al., 2015] and in studies by other groups [Battaglia et al., 2003; Chung et al., 2006] . In vitro aminoglycoside toxicity is a common model for investigating ototoxicity, and several recent studies using gentamicin revealed critical intracellular events that mediate HC survival [Battaglia et al., 2003; Brand et al., 2015; Caelers et al., 2010; Chung et al., 2006] . Interestingly, we found that brimonidine itself significantly reduced OHC loss in OC samples that were exposed to gentamicin plus brimonidine compared to samples exposed only to gentamicin. Brimonidine showed a protective effect on OHCs but not on IHCs. The receptor density of all of the α 2 -AR subtypes are equal on OHCs and IHCs on P3 and P8 [Cai et al., 2013b] . We investigated P5 rats, and we assumed that the IHCs and OHCs had the same α 2 -AR density. One possible reason for the protective effect of brimonidine that we observed for OHCs but not IHCs is that IHCs were less damaged by gentamicin than OHCs. OHCs are often more sensitive to damage than IHCs, partly because of intrinsically greater susceptibility [Sha et al., 2001] . Furthermore, the activation of G protein-coupled receptors has been shown to regulate diverse signaling pathways [Rosenbaum et al., 2009] , and the availability of specific pathway components may differ between the auditory HC types.
There are no previous reports of brimonidine-induced intracellular events in auditory HCs. However, our results are in line with other studies that found brimonidine-mediated protection in distinct experimental injury models in the visual system [Kim et al., 2007; Knels et al., 2008; Lai et al., 2002] . The retina and the inner ear share some common characteristics: both have a neuroepithelial origin, both contain sensitive sensory cells together with supporting cells, and both have a highly organized microarchitecture. Therefore, the molecular mechanisms involved in brimonidine-mediated protection in the retina may be similar to those involved in HCs. Moreover, brimonidine acts as a neuroprotective agent for the spiral ganglion [Cai et al., 2013a] , supporting the idea that brimonidine has protective activity in the inner ear.
Yohimbine, an α 2 -AR antagonist, blocked the protective effect of brimonidine. This is important because it suggests that the protective effect of brimonidine requires activation of the α 2 -AR and hence is mediated by the α 2 -AR itself. Cai et al. [2013a] found similar results in that yohimbine blocked the protective effects of brimonidine against glutamate and hydrogen peroxide toxicity. In the visual system, the protective effects of brimonidine were also blocked by yohimbine [Lai et al., 2002] . These observations raised the question of how to explain the observed protective effects of brimonidine and the relationship of these effects to α 2 -AR. We investigated this, and discuss some possible mechanisms below.
Brimonidine Does Not Change the Expression Level of the α 2 -AR Protein
Brimonidine is a strong agonist of the α 2a -AR and a weaker agonist of the α 2b -AR and the α 2c -AR [Peltonen et al., 1998 ]. To investigate whether brimonidine upregulated α 2a -AR, we investigated α 2a -AR protein expression levels. Exposure of OCs to gentamicin, brimonidine, and/ or yohimbine for 8 h did not result in significant differences in the expression level of the α 2a -AR protein in the different conditions, indicating that brimonidine neither upregulates nor downregulates the α 2a -AR. Interestingly, Cai et al. [2013a] reported that after 24 h of exposure to hydrogen peroxide and brimonidine, the α 2a -AR protein level was unchanged compared to the hydrogen peroxide-only treated groups, whereas after treatment with glutamate and brimonidine, the α 2a -AR level was upregulated compared to the glutamate-only groups. However, α 2a -AR was not upregulated in the glutamate-and brimonidine-treated groups compared to the untreated control groups in the present study. This indicates that glutamate 133 downregulated the α 2a -AR and that brimonidine did not significantly change the expression level of the α 2a -AR protein. Taken together, our results and the results of Cai et al. [2013a] indicate that the effect of brimonidine is not mediated by a change in the expression level of the α 2a -AR protein.
Brimonidine Does Not Significantly Change the Activation Levels of the Erk1/2 and Akt Proteins
Our experiments indicated that brimonidine does not significantly change the activation levels of the Erk1/2 protein. Because there was no statistically significant effect, our data does not clarify the effect of brimonidine on Erk1/2 activation. Therefore, we can only speculate about a p-Erk1/2-mediated protective effect on HCs. Erk1/2 plays a role in several cell functions [Kurioka et al., 2015; Lahne and Gale, 2008] . In HCs, Erk proteins are involved in both cell survival [Bas et al., 2012; Battaglia et al., 2003; Kurioka et al., 2015] and cell death [Kalinec et al., 2005; Lahne and Gale, 2008] , playing a complex role in the regulation of distinct cellular responses. The reports of the effects of brimonidine treatment on Erk1/2 activation have been contradictory; some studies report that brimonidine increases p-Erk1/2 levels [Fujita et al., 2013; Lai et al., 2002] , while others report that it decreases p-Erk1/2 levels [Cai et al., 2013a; Harun-Or-Rashid et al., 2015] . In our study, Erk1/2 activation levels were measured in whole OC explants, so it is not possible to tell whether Erk1/2 activation occurred in supporting cells, as reported by Lahne and Gale [2008] or in HCs themselves.
Brimonidine does not significantly change the activation levels of the Akt protein after 8 or 24 h of exposure. In the visual system, brimonidine activates the PI3 kinase pathway [Knels et al., 2008; Yukita et al., 2016] and also leads to Akt phosphorylation [Kim et al., 2007; Lai et al., 2002; Tatton et al., 2001] . Interestingly, the PI3 kinase pathway has been shown to mediate HC survival of gentamicin-induced toxicity [Chung et al., 2006] . Moreover, our group showed that Akt2 and Akt3 are involved in HC survival in response to gentamicin-induced toxicity . Because of these contradictory results, it seems possible that p-Erk1/2 and p-Akt might not be the direct targets of brimonidine.
In addition to these molecular mechanisms, the neuroprotective effects of brimonidine are also due to a reduction in NMDA-elicited intracellular signals [Dong et al., 2008; Han and Wu, 2002] . Notably, NMDA receptors in the cochlea may be involved in the ototoxic effects of aminoglycosides, and NMDA receptor antagonists attenuate these ototoxic effects [Basile et al., 1996; Nagy et al., 2004] . Furthermore, brimonidine blocks increases in Bax, caspase-9, and caspase-3 [Cai et al., 2013a] , abolishes the generation of reactive oxygen species [Knels et al., 2008] , and upregulates antiapoptotic genes such as Bcl-2 [Lai et al., 2002] . Caspase inhibition, inhibition of reactive oxygen species, and a protective role of Bcl-2 all promote HC survival [Cheng et al., 2005] . Brimonidine also upregulates growth factors [Gao et al., 2002; Kim et al., 2007; Lonngren et al., 2006] , and growth factors attenuate noise-induced hearing loss and increase OHC survival [Shoji et al., 2000] .
In our study, it is not clear which mechanisms are involved in the protective effects of brimonidine against gentamicin-induced toxicity in HCs. It is possible that these mechanisms act in concert to produce the observed effects or that there are as-yet undiscovered mechanisms or secondary messengers responsible for the otoprotective effects. Furthermore, the functional relevance and contribution of these protective mechanisms to HC survival may depend on the type of cellular injury and on the metabolic state of the cells. Future studies that investigate the precise molecular mechanisms underlying brimonidine's protective effect on HCs will increase our understanding of cell survival mechanisms in auditory HCs.
Conclusions
To the best of our knowledge, this is the first paper to study the effects of brimonidine on auditory HCs. We found that brimonidine can protect auditory HCs from gentamicin-induced ototoxicity in vitro and most likely does so through α 2 -AR signaling.
Very little is known about the role of the α 2 -AR in auditory HCs. Future research that investigates the precise molecular mechanisms that underlie the protective effect of α 2 -AR signaling in HCs may shed more light on our understanding of HC cell survival mechanisms. Finally, the α 2 -AR agonist brimonidine has a protective effect on HCs as well as on the spiral ganglion [Cai et al., 2013a] , and it shows potential for the prevention and/or treatment of sensorineural hearing loss in the future.
